LOUISVILLE — AntriaBio Inc. (OTC: ANTB), a pharmaceutical company that specializes in developing drug therapies for patients with diabetes and metabolic diseases, has raised $6.7 million.
The Louisville-based company is seeking to raise $15 million, according to a Form D filed with the Securities and Exchange Commission on May 30.
Sponsored Content
Register today for the 2022 Book of Lists Launch Party!
BizWest will unveil the 2022 Book of Lists at a special celebration with businesses that rank at the top of their lists and who are critical to the region’s economic growth. Join us on January 20 at Grace Place in Berthoud for drinks and hors d’oeuvres at the year’s first B2B event. Sponsored by fnbo.
AntriaBio did not return requests for comment.
The company has 45 employees. Its main product, according to its website, is AB101, a once-a-week basal insulin for patients with Type 1 and Type 2 diabetes.
In early May, AntriaBio launched the first in-human study of AB101. The company said it plans to file a new drug application with the FDA this month.
LOUISVILLE — AntriaBio Inc. (OTC: ANTB), a pharmaceutical company that specializes in developing drug therapies for patients with diabetes and metabolic diseases, has raised $6.7 million.
The Louisville-based company is seeking to raise $15 million, according to a Form D filed with the Securities and Exchange Commission on May 30.
Sponsored Content
2022 Economic Forecast: Registration is open!
Presented by BizWest: Thursday, January 27, 2022 from 11 a.m. to 1:30 p.m. at Embassy Suites in Loveland, CO featuring Keynote Speaker Richard L. Wobbekind - Associate Dean for Business & Government Relations, Senior Economist and Faculty Director of the Business Research Division at the University of Colorado Boulder.
AntriaBio did not return requests for comment.
The company has 45 employees. Its main product, according to its website, is AB101, a once-a-week basal insulin for patients with Type 1 and Type 2 diabetes.
In early May, AntriaBio launched the first in-human study of AB101. The company said it plans to file a new drug application with the FDA this month.
…
This article has been intentionally blurred.
You must purchase a subscription to view the rest of this content.
Want to See More!?
OR
Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!
Online access PLUS print versions of all Bizwest publications
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
Online access for one year.
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
Online and print versions of all Bizwest publications PLUS premium access to BizWest Datastore for one year.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to unlimited downloads from the BizWest Datastore!
- 1-year premium online access to the ALL NEW Breaking Ground website!
